Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

NCT04768296 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Small-cell Lung Cancer

Interventions

DRUG: Berzosertib
DRUG: Berzosertib
DRUG: Topotecan

Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

[object Object]